Small Molecule Drug Reverses ADAR1-induced Cancer Stem Cell Cloning Capacity
University of California San DiegoUC San Diego researchers report that a late-stage, pre-clinical small molecule inhibitor reverses malignant hyper-editing by a protein that promotes silencing of the immune response, metastasis and therapeutic resistance in 20 different cancer types.